[关键词]
[摘要]
目的 观察荜铃胃痛颗粒联合雷贝拉唑治疗肝胃不和型非糜烂性反流病的临床疗效。方法 选取2019年12月—2020年10月在天津中医药大学第一附属医院就诊的60例肝胃不和型非糜烂性反流病患者,按照随机数字表法分为对照组和治疗组,每组各30例。对照组口服雷贝拉唑钠肠溶胶囊,20 mg/次,1次/d;治疗组患者在对照组的基础上口服荜铃胃痛颗粒,5 g/次,3次/d。两组患者均治疗4周。观察两组患者临床疗效,比较治疗前后两组患者中医证候评分和生活质量。结果 治疗后,治疗组总有效率为93.33%,明显高于对照组的73.33%(P<0.05);治疗后,两组患者中医各项证候积分比治疗前显著下降(P<0.05),且治疗组患者改善显著优于对照组(P<0.05);治疗后,两组RQS评分均较前升高(P<0.05),且治疗组明显优于对照组(P<0.05)。结论 荜铃胃痛颗粒联合雷贝拉唑治疗肝胃不和型非糜烂性反流病疗效较好,可显著改善患者临床症状,具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To observe the clinical efficacy of Biling Weitong Granules combined with rabeprazole in treatment of non erosive reflux disease of liver-stomach disharmony. Methods Patients (60 cases) with non erosive reflux disease of liver-stomach disharmony in the First Teaching Hospital of Tianjin University of TCM from December 2019 to October 2020 were randomly divided into control and treatment groups, and each group had 30 cases. Patients in the control group were po administered with Rabeprazole Sodium Enteric Capsules, 20 mg/time, once daily. Patients in the treatment group were po administered with Biling Weitong Granules, 5 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the TCM syndrome scores and the RQS scores in two groups before and after treatment were compared. Results After treatment, the total effective rate in the treatment group was 93.33%, which was significantly higher than 73.33% in the control group (P < 0.05). After treatment, the TCM symptom scores in two groups were significantly lower than those before treatment (P < 0.05), and the improvement in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, the RQS scores in two groups were higher than those before treatment (P < 0.05), and which in the treatment group was significantly better than that in the control group (P < 0.05). Conclusion Biling Weitong Granules combined with rabeprazole has a good effect on the treatment of non erosive reflux disease of liver-stomach disharmony, which can significantly improve the clinical symptoms and has a certain clinical application value.
[中图分类号]
R975
[基金项目]
国家重点研发计划课题(2019YFC1709604)